Decipher Prostate is Now Covered by Medicare
for ALL Localized Disease
Know More With Decipher
Every patient and their prostate cancer is unique, and Decipher genomic testing provides meaningful and independent data to assess the underlying biology and risk of an individual patient’s disease. When used in conjunction with clinical information, Decipher provides clarity and confidence in treatment planning.
Decipher Prostate Covers 7 Cancer Pathways
Decipher Prostate was developed from a large cohort of metastatic and non-metastatic prostate cancer patients treated at the Mayo Clinic. The whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.
Which Decipher Test Should I Order for My Patients?
Decipher Prostate Biopsy helps determine if patients are suitable for active surveillance, if they need monotherapy, or if they may benefit from multi-modality or intensified therapy.
Decipher Prostate RP helps determine treatment timing following radical prostatectomy and whether patients undergoing salvage radiotherapy may benefit from the addition of ADT.
Is Decipher Covered by Medicare and Commercial Insurance?
- Medicare provides coverage for Decipher for all beneficiaries with localized prostate cancer
- Many commercial insurance plans provide coverage for Decipher
- Decipher is committed to providing access to genomic testing for all patients. Financial assistance is available via the Decipher Assist program
Decipher has been broadly validated across all localized disease
Decipher has been validated in 75+ studies across more than 60,000 patients for metastasis, prostate cancer-specific mortality, and overall survival